MCM
SABS icon

MAI Capital Management’s SAB Biotherapeutics SABS Stock Holding History

MAI Capital Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$832 Hold
217
– – ﹤0.01% 4244
2025
Q4 		$812 Hold
217
– – ﹤0.01% 3694
2025
Q3 		$437 Hold
217
– – ﹤0.01% 3639
2025
Q2 		$381 Hold
217
– – ﹤0.01% 3804
2025
Q1 		$296 Buy
217
+87
+67% +$200 ﹤0.01% 3285
2024
Q4 		$494 Buy
+130
New +$427 ﹤0.01% 3297

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MAI Capital Management's SABS Position: Q1 2026 in Review

MAI Capital Management held its SAB Biotherapeutics (SABS) position steady in Q1 2026 at 217 shares worth $832. The position accounts for ﹤0.01% of the portfolio, ranked #4244.

MAI Capital Management first reported a position in SABS in Q4 2024 and has held it in 6 quarters since. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • MAI Capital Management held 217 shares of SAB Biotherapeutics worth $832 as of Q1 2026.
  • MAI Capital Management left its SAB Biotherapeutics share count unchanged in Q1 2026.
  • SAB Biotherapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4244 holding.
  • MAI Capital Management first reported a position in SAB Biotherapeutics in Q4 2024 and has held it in 6 quarters since.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.